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Human T  cell ieukemia/lymphoma virus (HTLV)-I can infect and transform 
normal T  cells (1), and has also been found in some transformed B cell lines (2, 
3).  HTLV-I infection is associated  with a  profound increase in  the number of 
cell surface interleukin 2 (I L-2) receptors (containing the Tac antigen) on infected 
T  cells (1, 4). The ability of B lymphocytes to also express IL-2 receptors under 
certain conditions (2,  3,  5-7), and the precise manner by which  IL-2 affects B 
cell function, are areas of intense current interest (3, 5-8). Since we are interested 
in examining the effects of IL-2 on a homogeneous population of human B cells, 
we attempted to establish  HTLV-I-infected, IL-2 receptor-positive B  cell lines 
from normal human  B  cells. We show that  HTLV-I can infect normal mature 
human B cells in vitro, and that IL-2 can affect these B cells, through their IL-2 
receptor, to directly induce the differentiation of HTLV-I-infected B cells into 
Ig-secreting ceils, without affecting their proliferation. 
Materials and  Methods 
B Cell Purification.  Human tonsils were processed to obtain purified resting B cells 
using counterflow centrifugation elutriation (Model J-6B;  Beckman  Instruments,  Inc., 
Palo Alto,  CA)  as  previously described (6).  The smallest-sized  B  cell fractions (mean 
volume of 160-180 t~m 3) were >95% surface Ig-positive and <0.2% T3  ÷, as determined 
by fluorescence-activated cell sorter (FACS) analysis. 
HTLV-I Infection.  Cocultivation of the HTLV-I  + B cell line, HS 1, a B cell clone isolated 
from a female patient with HTLV-associated adult T  cell leukemia, with highly purified 
tonsillar small  resting B cells was carried out as previously described (2). After 2 wk in 
culture, cell lines grew spontaneously and displayed growth in  large clumps. Cell lines 
obtained from coculture of HS1  and  unactivated B  cells  were called B-HTLV. After 
several weeks in culture, the cell line was examined for HLA phenotype and determination 
of HTLV infection. Cells infected with HTLV-1 were identified by indirect immunoflu- 
orescence using a monoclonal antibody (mAb) against p19, an HTLV-I-encoded protein 
in the cytoplasm of the infected cell, and by Southern blot hybridization using an HTLV- 
I pol-env-pX probe. Clonal derivatives were obtained from B-HTLV by limiting dilution, 
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with cells seeded at mean concentrations of 10,  5,  1, and 0.3 cells/well. A positive well 
was selected for further characterization from plates seeded at the lowest cell concentration 
(0.3 cells/well) where only 3 of 120 wells were positive. This line was designated STB-1. 
These cell lines and clones have thus far been maintained for 4 mo in culture. 
Southern Blotting Study.  Southern blot hybridization was processed using a DNA probe, 
a 32p-nick-translated DNA insert from a subclone in pBR322 of the portions of the HTLV- 
I  genome defined by the Cla I and  Hind  III sites  of ~CR-1  and containing pol-env-pX 
sequences (9). 
Celt Staining.  The mAb used to stain cells for FACS analysis were: anti-Tac in ascites 
form, generously provided by Dr. Thomas Waldmann (NIH); control ascites (P3X63); 
OKT3  (Ortho  Diagnostic  Systems,  Inc.,  Raritan,  NJ);  and  Leu-1  or  Leu-12  (Becton 
Dickinson Monoclonal Center, Inc., Mountain View,  CA). Surface Ig staining was done 
directly with fluorescent goat anti-human Ig (Cappel Laboratories, Cochranville, PA). 
Factors.  Concanavalin A (Con A)-stimulated supernatant was prepared by coculturing 
peripheral blood mononuclear cells of two allogeneic donors in the presence of Con A 
(10 #g/ml). Purified IL-1 (Genzyme Corp., Boston, MA), recombinant IL-2 (Lot LP210; 
provided by Cetus Corp., Emeryville, CA), and recombinant ~,-interferon (I FN-7) (Genen- 
tech Corp., So. San Francisco, CA) were used in this study. B cell growth factor (BCGF) 
was derived from a B cell line, Namalva, as previously described (10). 
Culture  Conditions and Assays.  HTLV-I-infected B cell lines or clones were cultured 
in  0.2 ml of RPMI-1640 supplemented with  10%  fetal calf serum, and gentamicin (20 
ttg/ml) in 96-well,  flat-bottomed microtiter plates (3072; Falcon Labware, Oxnard, CA) 
at  a  cell density of 5  x  103  cells/well.  Assays  for proliferation and  differentiation of 
cultured cells were done as previously described (6). 
Results and Discussion 
Development of HTLVoI-infected B  Cell Clones In  Vitro.  The cell surface char- 
acteristics of the cell lines used are listed in Table I. The newly established cell 
lines could be distinguished  from HS1  by differences in sex chromosomes and 
HLA antigens,  HS1  was  isolated  from a  female patient,  and  expressed  HLA- 
DR3, MT1, and MT2. The new cell lines (B-HTLV, and STB-1) contained a  Y 
chromosome, and expressed HLA-DR6, DR10, MT1, and MT2. These cell lines 
expressed B ceil-associated antigens, surface Ig and Leu-12, but neither of the 
T  cell markers,  Leu-1  nor T3.  They also expressed the  HTLV-encoded viral 
protein,  p19,  in  their  cytoplasm.  In  addition,  we  determined  whether  STB-1 
cells were infected with HTLV-I by Southern blot hybridization (Fig.  1). When 
DNA  from the ceils were digested  with Barn HI and hybridized with  HTLV-I 
pol-env-pX  probe,  three  distinct  bands  and  three  thin  bands,  which  contained 
TABLE  I 
Characterization of HTL V-l-infected Cells 
Marker  Normal  B  HS1 *  B-HTLV*  STB-1 ~ 
cells 
Surface  lg  +  +  +  + 
Leu- 12  +  +  +  + 
Leu-I  .... 
OKT3  .... 
p19  -  +  +  + 
Tac  -  +  +  + 
HLA-DR  +  +  +  + 
*  HSI  is an HTLV-l-transformed  B cell clone  isolated  from a  patient  with HTLV- 
l-associated adult T  cell leukemia. 
* B-HTLV  is an  HTLV-l-infected  B  cell  line  obtained  by  coculture  of HSI  with 
unactivaled  B  cells. 
a STB-1  is a  B cell clone obtained  from the B-HTLV  cell  line by limiting dilution. TOMITA  ET  AL.  BRIEF  DEFINITIVE REPORT  395 
FIGURE  1.  Proviral sequences of HTLV-I in clone STB-1. DNA digested with Pst I and Bam 
HI was analyzed by Southern blot.  DNA was obtained from STB-1,  an HTLV-Iea-bearing 
tumor cell line,  HUT-102, and an EBV-transformed,  HTLV-Iouninfected B cell line, CR-B. 
Proviral bands are indicated,  and sizes, in kb, are shown. 
Barn  HI  junction  fragments,  were  obtained,  indicating  that  three  copies  of 
HTLV-I  were integrated  in this population.  A  distinct band of 1.1  kilobases (kb) 
was also observed, which is common to all HTLV-I-infected cells, and represents 
an  internal  fragment  of the  provirus.  This  indicates  that  there  is  not  a  large 
internal  deletion  of the  proviruses  in  STB-1  cells.  Digestion  with  Pst  I  resulted 
in the internal  fragment of 2.5 kb and three junction fragments, confirming that 396  TOMITA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Responses of HTLV-I-infected B Cells to Various Lymphokines 
[~H]Thymidine 
Cells  Lymphokine  Dose  uptake*  IgM production* 
HSI 
B-HTLV 
STB- 1 
cpm  ng/ml 
Background  --  1,144 -+  189  1,138 ±  60 
Con A supernatant*  10% vol/vol  2,579 ±  102  4,345 -+ 771 
IL-2  25 U/ml  1,679 +  80  1,530 -  80 
Background  --  1,432 -+ 171  171  -  31 
Con A supernatant  10% vol/vol  1,077 +  14  728 +  100 
IL-2  25 U/ml  1,153 +  85  1,301 _+  102 
Background  I  1,162 -+ 81  193 -+  15 
Con A supernatant  10% vol/vol  1,489 +- 153  520 +  35 
IL-2  25 U/ml  1,274 +  25  1,279 +  48 
IL-I  5 U/ml  1,265 -+ 336  137 +  13 
IFN-3,  200 U/ml  1,256 -  130  t78 +-  14 
BCGF-Namalva  10% vol/vol  1,412 +  I09  180 -+  18 
* For details of assays, see Materials and Methods. Data represent mean +_ SEM of triplicate cultures. 
* Con A supernatant contained 8 U/ml of IL-2. 
three oligoclonal proviral integrations took place  in this population. The new 
cell lines were also tested for Epstein-Barr virus (EBV)  infection, as determined 
by the presence of Epstein-Barr nuclear antigen (EBNA). Some cells of each cell 
line expressed a small amount of EBNA. However, at the time we infected the 
small  B  cells  with  HTLV-I,  EBNA  was  undetectable.  Thus,  they  still  were 
"normal" B cells at the time they became transformed with HTLV-I. 
Nonactivated small resting B cells  are  negative for Tac antigen, whereas in 
vitro-activated B cells do express Tac antigen on their surface (3, 5-7). As shown 
in Table  I,  expression of Tac antigen on the cell surface of normal resting B 
cells  was induced by in  vitro infection with HTLV. Several investigators have 
demonstrated a strong correlation between the expression of Tac antigen on T 
cells and infection with HTLV-I (1,  4).  This suggests that HTLV may either 
upregulate the expression of Tac antigen on infected cells, or may itself produce 
a protein, similar or identical to the Tac antigen, that becomes expressed on the 
cell surface, but there is little evidence for HTLV-I encoding a Tac-like antigen 
(11).  Nevertheless, the possibility that HTLV-I selectively infected a small num- 
ber of already Tac  + cells cannot be ruled out by this study. 
Responses of HTL V-I-infected  B Cells to Various Lymphokines.  To determine the 
effect of various lymphokines on HTLV-I-infected B cells,  cells were incubated 
at 5  ×  10 a cells/well with a variety of lymphokines, after which DNA synthesis 
and Ig production were measured (Table II). HS 1 cells spontaneously produced 
IgM, but not IgG or IgA, in the absence of lymphokines.This cell line could be 
induced to produce additional IgM by Con A supernatant (containing a variety 
of iymphokines, including IL-2 and B cell differentiation factor). Low concentra- 
tions (25  U/ml) of IL-2 had little effect on the proliferation and differentiation 
of HS1.  The new lines, B-HTLV and STB-1, had a relatively low background 
secretion of IgM, and virtually no background secretion of IgG or IgA. However, 
B-HTLV responded well to IL-2 with an eightfold enhanced secretion of IgM. 
The same was true of STB-1, which secreted IgM in response to IL-2 to a greater 
degree than to the other lymphokines tested. IL-2 did not enhance the prolifer- 
ation of these B cells at any concentration tested (0.8-100 U/ml). Fig. 2 A shows TOMITA  ET  AL.  BRIEF  DEFINITIVE REPORT  397 
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FIGURE 2.  (A) Concentration-dependent  effect of IL-2 on the differentiation  of an HTLV- 
I-infected B cell clone, STB-I. Data represent the mean "4- SEM of triplicate cultures. (B) Effect 
of anti-Tac antibody on the IL-2 induced differentiation  of an HTLV-I-infected B cell clone, 
STB-1. STB-1 cells cultured  with 25 U/ml of recombinant  IL-2 in the presence of anti-Tac 
ascites (O  (3) or control ascites P3X63 (0-----0). Data are expressed as percent inhibition 
of the response obtained in cultures receiving medium or recombinant  IL-2 alone (195 +  1.5 
ng/ml and 1,570 + 29 ng/ml), respectively. 
the  concentration-dependent  effect of recombinant  IL-2 on  the  differentiation 
of STB-1,  as measured  by the  secretion  of IgM.  Neither  highly purified  IL-1, 
recombinant  IFN-y,  nor  BCGF  produced  by  the  B  cell  line  Namalva  (10) 
modulated DNA synthesis or IgM production by the clone STB-1 at any concen- 
tration tested.  Clearly, IL-2 alone can induce substantial  IgM production in this 
system. 
The  IL-2-induced  differentiation  of STB-1  cells  was  notably  inhibited,  in  a 
concentration-dependent  manner,  by the  addition  to  culture  of anti-Tac anti- 
body, but not by control ascites (P3X63) (Fig. 2 B). In addition, anti-Tac antibody 
had no effect on the background proliferation  of STB-1  cells (data not shown). 
These data suggest that Tac antigen found on the HTLV-I-infected B cell clone 
STB-1  has  functional  importance  in  the  IL-2-induced  differentiation  of  this 
clone. 
The  interaction  beween  IL-2 and  its receptor on  B  cells is of interest.  Ralph 
et al. (8) shows that Tac antigen  was not  involved in the  IL-2-induced differen- 
tiation of EBV-transformed B cells. However, as Waldmann et al. (3) have shown, 
EBV-transformed  B  cell  lines  derived  from  Tac  +,  activated  normal  B  cells 
continued  to  express  Tac  antigen,  and  were  induced  to  differentiate  by  the 
addition  of IL-2.  In addition,  Tsudo  et al.  (5) suggested that  IL-2 induced  the 
proliferation of normal activated B cells via the IL-2 receptor, as defined by the 
Tac antigen.  These observations,  taken  in  conjunction  with  this study,  suggest 
that the IL-2 receptor is induced in certain subsets of B ceils, or B cells at certain 
stages of differentiation,  and  that  IL-2 can perform an  important role in B  cell 
maturation  through  its receptor.  Furthermore,  HTLV-I, different  from  EBV, 
may induce  B  cells to  respond  to  IL-2 by inducing  the  expression  of the  IL-2 
receptor.  However,  it  is  still  not  clear  whether  the  IL-2  receptor  is  somehow 
closely associated with a differentiation receptor, or whether IL-2, acting through 
its own receptor on the responding cell, provides a second late differentiation or 
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Summary 
A  human  T  cell  leukemia/lymphoma  virus  (HTLV)-I-infected B  cell  clone 
expressed Tac antigen on its cell surface and responded to recombinant interleu- 
kin 2 (IL-2) by increased production of IgM without any increase in proliferation. 
Anti-Tac antibody completely inhibited  the  IL-2-induced differentiation of this 
HTLV-I-infected B cell clone. This study demonstrates that HTLV-I can directly 
infect normal  mature  human  B  cells,  and  that  the  Tac antigen,  which  may be 
induced  by infection with  HTLV-I, is the  functional  receptor for IL-2-induced 
B cell differentiation. The availability of such cell lines and clones should provide 
useful  tools to  delineate  precisely the  differentiation  step in  the  human  B  cell 
cycle. 
We thank J.  Kehrl,  H. Mostowski, and J. Grove for their assistance,  I. Magrath and G. 
Armstrong for doing EBNA staining, and A. London for editorial assistance. 
Received for publication  25 February 1985. 
References 
1.  Broder, S.,  P.  A. Bunn,  E. S. Jaffe, w. Blattner, R. C. Gallo, F. Wong-Staal, T. A. 
Waldmann, and V. T. DeVita. 1984. T-cell lymphoproliferative syndrome associated 
with human T-cell leukemia/]ymphoma virus. Ann. Intern. Med.  100:543. 
2.  Longo, D. L., E. P. Gelmann, J. Cossman, R. A. Young, R. C. Gallo, S. J. O'Brien, 
and L. A. Matis.  1984. Isolation of HTLV°transformed B lymphocyte clone from a 
patient with HTLV-associated adult T  cell leukemia. Nature (Lond.).  310:505. 
3.  Waldmann, T. A., C. K. Goldman, R. J. Robb, J. M. Depper, W. J. Leonard, S. O. 
Sharrow, K. F. Bongiovanni, S.J.  Korsmeyer, and W. C. Greene.  1984.  Expression 
of interleukin 2 receptors on activated human B cells. J. Exp. Med.  160:1450. 
4.  Lando, Z., P.  Sarin, M.  Megson, W. C. Greene, T. A. Waldmann, R. C. Gallo, and 
S.  Broder.  1983.  Association of human  T-cell leukaemia/lymphoma virus with the 
Tac antigen  marker for the  human T-cell growth  factor receptor. Nature  (Lond.). 
305:733. 
5.  Tsudo,  M.,  T.  Uchiyama,  and  H.  Uchino.  1984.  Expression  of Tac  antigen  on 
activated normal human B cells.J. Exp. Med.  160:612. 
6.  Muraguchi,  A., J.  H.  Kehrl,  D.  L.  Longo, D. J.  Volkman,  K.  A.  Smith, and  A. S. 
Fauci.  1985.  Interleukin 2 receptors on human B cells.  Implications for the role of 
interleukin 2 in human B cell function. J. Exp. Med.  161:181. 
7.  Nakagawa,  T.,  T.  Hirano,  N.  Nakagawa,  K.  Yoshizaki,  and  T.  Kishimoto.  1985. 
Effect of recombinant IL-2 and 7-IFN on proliferation and differentiation of human 
B cells.J, lmmunol.  134:959. 
8.  Ralph, P., G. Jeong, K. Welte, R. Mertelsmann, H. Rabin, L. E. Henderson, L. M. 
Souza, T. C. Boone, and R.J. Robb. 1984. Stimulation of immunoglobulin secretion 
in human B lymphocytes as a direct effect of high concentrations of IL-2. J. Immunot. 
133:2442. 
9.  Manzari, V., F. Wong-Staal, G. Franchini, S. Colombini, E. P. Gelmann, S. Oroszlan, 
S. Staal, and R. C. Gallo, 1983. Human T-cell leukemia-lymphoma (HTLV): cloning 
of integrated defective provirus and flanking cellular sequences. Proc. Natl. Acad. Sci. 
USA.  80:1574. 
10.  Ambrus, J. L., and A. S. Fauci.  1985. Human B lymphoma cell line producing B cell 
growth factor. J. Clin. Invest.  75:732. 
11.  Leonard, W. J., J. M. Depper, G. R. Crabtree, S. Rudikoff, J. Pumphrey, R.J. Robb, 
M. Kr6nke, P.  B. Svetlik, N.J.  Peffer, T. A. Waldmann, and W. C. Greene.  1984. 
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. 
Nature (Lond.).  311:626. 